alpha 1B adrenergic receptor Agonists
1 drugsAbout alpha 1B adrenergic receptor
The alpha 1B adrenergic receptor (α1B-AR) is a G protein-coupled receptor that mediates the effects of norepinephrine and epinephrine. It is a subtype of the alpha-1 adrenergic receptor family and plays a crucial role in various physiological processes.
The α1B-AR is a relevant target for pharmaceutical intervention, though there is currently no genetic evidence directly linking it to specific diseases. The existence of an FDA-approved drug suggests the viability of α1B-AR as a drug target.
Currently, one FDA-approved drug, TAMSULOSIN HYDROCHLORIDE (Novartis), targets this receptor as a small molecule. The current therapeutic area associated with α1B-AR targeting falls into the 'Other' category.
Top alpha 1B adrenergic receptor Drugs
Novartis is the only company with an approved drug targeting alpha 1B adrenergic receptor.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in market development.
alpha 1B adrenergic receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets alpha 1B adrenergic receptor, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage and expand therapeutic applications.
alpha 1B adrenergic receptor Clinical Trials 73 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on alpha 1B adrenergic receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 10 | 9 | 0 | 1 | 100% |
| Phase 2 | 11 | 6 | 0 | 5 | 100% |
| Phase 3 | 20 | 10 | 6 | 4 | 63% |
| Phase 4 | 32 | 21 | 6 | 5 | 78% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
alpha 1B adrenergic receptor Drug Approval Timeline (2010 - 2010)
The first and most recent drug approval for this target was TAMSULOSIN HYDROCHLORIDE in 2010.
The lack of recent approvals suggests a saturated market or challenges in developing new therapies for this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 55 (14 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on alpha 1B adrenergic receptor. A trial counts if an approved drug acting on alpha 1B adrenergic receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.